UA85569C2 - Замещенные конденсированные гетероциклические с-гликозиды - Google Patents
Замещенные конденсированные гетероциклические с-гликозидыInfo
- Publication number
- UA85569C2 UA85569C2 UAA200605347A UAA200605347A UA85569C2 UA 85569 C2 UA85569 C2 UA 85569C2 UA A200605347 A UAA200605347 A UA A200605347A UA A200605347 A UAA200605347 A UA A200605347A UA 85569 C2 UA85569 C2 UA 85569C2
- Authority
- UA
- Ukraine
- Prior art keywords
- glycosides
- fused heterocyclic
- substituted fused
- substituted
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Данное изобретение относится к замещенным конденсированным гетероцикличным С-гликозидам, композициям, содержащим их, и способам их использования, например, для лечения или профилактики диабета и синдрома X.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49152303P | 2003-08-01 | 2003-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA85569C2 true UA85569C2 (ru) | 2009-02-10 |
Family
ID=34115512
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200605348A UA86042C2 (en) | 2003-08-01 | 2004-07-29 | Substituted indazole-o-glucosides |
UAA200605349A UA86599C2 (en) | 2003-08-01 | 2004-07-30 | Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides |
UAA200605346A UA87991C2 (en) | 2003-08-01 | 2004-07-30 | Substituted indole-o-glucosides |
UAA200602256A UA83377C2 (ru) | 2003-08-01 | 2004-07-30 | N-гликозид, способ его получения, фармацевтическая композиция и способ лечения |
UAA200605347A UA85569C2 (ru) | 2003-08-01 | 2004-07-30 | Замещенные конденсированные гетероциклические с-гликозиды |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200605348A UA86042C2 (en) | 2003-08-01 | 2004-07-29 | Substituted indazole-o-glucosides |
UAA200605349A UA86599C2 (en) | 2003-08-01 | 2004-07-30 | Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides |
UAA200605346A UA87991C2 (en) | 2003-08-01 | 2004-07-30 | Substituted indole-o-glucosides |
UAA200602256A UA83377C2 (ru) | 2003-08-01 | 2004-07-30 | N-гликозид, способ его получения, фармацевтическая композиция и способ лечения |
Country Status (18)
Country | Link |
---|---|
US (1) | US7521430B2 (ru) |
EP (1) | EP1654269B1 (ru) |
JP (1) | JP4717811B2 (ru) |
KR (1) | KR101101500B1 (ru) |
CN (2) | CN102060888A (ru) |
AU (1) | AU2004260760B2 (ru) |
BR (1) | BRPI0413233A (ru) |
CA (1) | CA2534022C (ru) |
EA (1) | EA011025B1 (ru) |
ES (1) | ES2527053T3 (ru) |
IL (1) | IL173051A (ru) |
MX (1) | MXPA06001273A (ru) |
NO (1) | NO333679B1 (ru) |
NZ (1) | NZ545305A (ru) |
TW (1) | TWI377209B (ru) |
UA (5) | UA86042C2 (ru) |
WO (1) | WO2005012321A1 (ru) |
ZA (2) | ZA200601686B (ru) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
ME00411B (me) * | 2003-08-01 | 2011-10-10 | Tanabe Seiyaku Co | Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma |
TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
JP5073948B2 (ja) * | 2005-01-31 | 2012-11-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
MY147375A (en) | 2005-01-31 | 2012-11-30 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
TWI418556B (zh) * | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
CA2671699C (en) * | 2006-12-04 | 2014-07-08 | Janssen Pharmaceutica N.V. | Thienyl-containing glycopyranosyl derivatives as antidiabetics |
UY30730A1 (es) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
CN101801371B (zh) | 2007-09-10 | 2012-11-28 | 詹森药业有限公司 | 可用作sglt抑制剂的化合物的制备方法 |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
WO2009143020A1 (en) | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
ES2380408T3 (es) | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
KR20110055740A (ko) * | 2008-09-19 | 2011-05-25 | 노파르티스 아게 | 글리코시드 유도체 및 그의 용도 |
US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
SI2451797T1 (sl) | 2009-07-10 | 2013-07-31 | Janssen Pharmaceutica, N.V. | Postopek kristalizacije 1-(beta-d-glukopiranosil)-4-metil-3-(5-(4-fluorofenil)-2-tienilmetil) benzena |
BR112012008939B1 (pt) * | 2009-10-14 | 2021-06-22 | Janssen Pharmaceutica Nv | Processo para a preparação de compostos úteis como inibidores de sglt2 |
ME02016B (me) | 2009-11-02 | 2015-05-20 | Pfizer | Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola |
EA022365B1 (ru) | 2010-05-11 | 2015-12-30 | Янссен Фармацевтика Нв | Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг |
CA2832938C (en) | 2011-04-13 | 2019-09-03 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
US9035044B2 (en) * | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
JP6173427B2 (ja) * | 2013-02-26 | 2017-08-02 | 田辺三菱製薬株式会社 | α−ハロテトラアシルグルコースの製造方法 |
CN103896930B (zh) * | 2014-04-02 | 2016-08-17 | 安徽联创生物医药股份有限公司 | 卡格列净半水合物药用晶型的制备方法 |
US9695159B2 (en) | 2014-05-27 | 2017-07-04 | Glenmark Pharmaceuticals Limited | Process for preparation of canagliflozin |
CN104045673B (zh) * | 2014-06-06 | 2017-01-18 | 安徽省食品药品检验研究院 | 双‑三氮唑缀合的假二糖衍生物及其制备方法 |
CN104478968A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
CN106188022A (zh) * | 2015-04-30 | 2016-12-07 | 上海医药工业研究院 | 伊格列净的制备方法 |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
JOP20210009A1 (ar) | 2018-07-19 | 2021-01-12 | Astrazeneca Ab | طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله |
WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
US20240212818A1 (en) | 2021-04-01 | 2024-06-27 | Astrazeneca Uk Limited | Systems and methods for managing prediabetes with a gliflozin sodiumglucose cotransport 2 inhibitor pharmaceutical composition |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1075626B (de) * | 1960-02-18 | Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M | Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden | |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
AU4114601A (en) * | 2000-03-17 | 2001-09-24 | Kissei Pharmaceutical | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
DE60122193T2 (de) * | 2000-09-29 | 2007-07-05 | Kissei Pharmaceutical Co., Ltd., Matsumoto | Glucopyranosyloxybenzylbenzol derivate und medizinische zusammensetzungen, die diese verbindungen enthalten |
AU2002223127A1 (en) * | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
US7084123B2 (en) | 2000-12-28 | 2006-08-01 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
TWI255817B (en) * | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
EP1432720A1 (en) | 2001-09-05 | 2004-06-30 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2004
- 2004-07-29 UA UAA200605348A patent/UA86042C2/ru unknown
- 2004-07-30 TW TW093122844A patent/TWI377209B/zh not_active IP Right Cessation
- 2004-07-30 AU AU2004260760A patent/AU2004260760B2/en not_active Ceased
- 2004-07-30 CN CN2010105463425A patent/CN102060888A/zh active Pending
- 2004-07-30 UA UAA200605349A patent/UA86599C2/ru unknown
- 2004-07-30 UA UAA200605346A patent/UA87991C2/ru unknown
- 2004-07-30 MX MXPA06001273A patent/MXPA06001273A/es active IP Right Grant
- 2004-07-30 EP EP04771313.6A patent/EP1654269B1/en not_active Not-in-force
- 2004-07-30 NZ NZ545305A patent/NZ545305A/en not_active IP Right Cessation
- 2004-07-30 UA UAA200602256A patent/UA83377C2/ru unknown
- 2004-07-30 UA UAA200605347A patent/UA85569C2/ru unknown
- 2004-07-30 EA EA200600348A patent/EA011025B1/ru not_active IP Right Cessation
- 2004-07-30 JP JP2006519250A patent/JP4717811B2/ja not_active Expired - Fee Related
- 2004-07-30 US US10/566,585 patent/US7521430B2/en not_active Expired - Fee Related
- 2004-07-30 ES ES04771313.6T patent/ES2527053T3/es active Active
- 2004-07-30 BR BRPI0413233-5A patent/BRPI0413233A/pt not_active IP Right Cessation
- 2004-07-30 CA CA2534022A patent/CA2534022C/en not_active Expired - Fee Related
- 2004-07-30 CN CNA2004800220063A patent/CN1829728A/zh active Pending
- 2004-07-30 KR KR1020067002158A patent/KR101101500B1/ko not_active IP Right Cessation
- 2004-07-30 WO PCT/JP2004/011311 patent/WO2005012321A1/en active Application Filing
-
2006
- 2006-01-10 IL IL173051A patent/IL173051A/en not_active IP Right Cessation
- 2006-01-16 NO NO20060219A patent/NO333679B1/no not_active IP Right Cessation
- 2006-02-27 ZA ZA200601686A patent/ZA200601686B/en unknown
- 2006-05-15 ZA ZA200603880A patent/ZA200603880B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007518682A (ja) | 2007-07-12 |
TWI377209B (en) | 2012-11-21 |
AU2004260760B2 (en) | 2009-08-13 |
NO333679B1 (no) | 2013-08-05 |
WO2005012321A1 (en) | 2005-02-10 |
US20070060545A1 (en) | 2007-03-15 |
UA86042C2 (en) | 2009-03-25 |
NO20060219L (no) | 2006-04-28 |
ZA200603880B (en) | 2010-01-27 |
EA200600348A1 (ru) | 2006-08-25 |
CA2534022A1 (en) | 2005-02-10 |
IL173051A0 (en) | 2006-06-11 |
JP4717811B2 (ja) | 2011-07-06 |
US7521430B2 (en) | 2009-04-21 |
EA011025B1 (ru) | 2008-12-30 |
CN1829728A (zh) | 2006-09-06 |
ES2527053T3 (es) | 2015-01-20 |
AU2004260760A1 (en) | 2005-02-10 |
EP1654269A1 (en) | 2006-05-10 |
IL173051A (en) | 2012-06-28 |
TW200510440A (en) | 2005-03-16 |
UA87991C2 (en) | 2009-09-10 |
NZ545305A (en) | 2008-11-28 |
CN102060888A (zh) | 2011-05-18 |
KR20060132539A (ko) | 2006-12-21 |
BRPI0413233A (pt) | 2006-10-03 |
ZA200601686B (en) | 2007-05-30 |
EP1654269B1 (en) | 2014-10-15 |
CA2534022C (en) | 2012-10-02 |
UA86599C2 (en) | 2009-05-12 |
MXPA06001273A (es) | 2006-04-11 |
UA83377C2 (ru) | 2008-07-10 |
KR101101500B1 (ko) | 2012-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA85569C2 (ru) | Замещенные конденсированные гетероциклические с-гликозиды | |
WO2005012318A3 (en) | Substituted fused heterocyclic c-glycosides | |
WO2005012242A3 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides | |
RS20060320A (en) | Substituted indazole-o-glucosides | |
MY142777A (en) | Substituted indole-o-glucosides | |
MX2007003108A (es) | Compuestos imidazo-3-il-amina sustituidos y biciclicos. | |
TN2009000111A1 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
MX2007005221A (es) | Formas cristalinas de ascomicina y preparacion de ellas. | |
NO20044221L (no) | Nye forbindelser | |
EP1590336A4 (en) | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | |
UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
PL1682530T3 (pl) | Podstawione pirolo-indole jako inhibitory PAI-1 | |
MXPA05009885A (es) | Nuevas triazolonas fusionadas y los usos de las mismas. | |
TW200616977A (en) | Enantiomers of selected fused heterocyclics and uses thereof | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
PL1620425T3 (pl) | Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu | |
TW200621260A (en) | Selected fused heterocyclics and uses thereof | |
MXPA06000986A (es) | Compuestos. | |
BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
DE60316128D1 (de) | N-sulfonylurea-apoptosis-förderer | |
MXPA06000987A (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
MXPA04004090A (es) | Compuestos substituidos de 1h-quinolin-2-ona. |